What is the standard of care for locally advanced Breast Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Breast Cancer (NCCN Guidelines)

Based on the NCCN Guidelines for Invasive Breast Cancer (Version 5.2025), here's what constitutes standard care for locally advanced disease:

Key Treatment Approach: Preoperative (Neoadjuvant) Systemic Therapy

The standard approach for locally advanced breast cancer typically involves systemic therapy given BEFORE surgery, rather than after. This is called preoperative or neoadjuvant therapy.

Why This Approach?

According to NCCN Guidelines, preoperative systemic therapy offers several advantages:

• Similar long-term outcomes compared to giving the same treatment after surgery
• Allows time for genetic testing to identify inherited cancer risk
• Enables breast reconstruction planning if mastectomy is needed
• Provides a research platform to test new therapies
• May convert inoperable disease to operable disease in some patients

Treatment Components by Breast Cancer Subtype

The specific therapy depends on your cancer's characteristics:

HER2-Positive Disease (≥cT2 and/or cN+)

• HER2-directed therapy is recommended as part of preoperative treatment
• Combined with chemotherapy regimens

ER-Positive (Hormone Receptor-Positive) Disease

• Preoperative endocrine therapy alone may be considered for patients with:
  • Specific comorbidities (other health conditions)
  • Low-risk luminal biology (less aggressive subtype)
  • Optimal response typically achieved between 4-6 months

Triple-Negative Breast Cancer (TNBC)

• Chemotherapy-based regimens are standard
• Pathologic complete response (pCR) to preoperative therapy is associated with extremely favorable long-term survival

Important Monitoring During Treatment

According to NCCN Guidelines:

• Tumor response should be routinely assessed by clinical exam and imaging during therapy
• The standard regimen should be completed before surgery when possible
• If disease progresses during preoperative therapy, your oncologist may recommend an alternate regimen or proceed to surgery

Pathology Evaluation After Surgery

After preoperative therapy and surgery, your pathology report should include:

• Residual Cancer Burden (RCB) assessment - this measures how much cancer remains after treatment and helps predict outcomes
• Pathologic complete response (pCR) - when no cancer cells are found - is associated with excellent disease-free and overall survival, particularly for TNBC

Locoregional Therapy (Radiation/Surgery)

Following preoperative systemic therapy:

• Surgery to remove the breast tumor and evaluate lymph nodes
• Radiation therapy may be recommended based on:
  • Extent of lymph node involvement
  • Presence of extranodal extension (cancer spreading outside the lymph node)
  • Other high-risk features

Key Questions to Ask Your Oncology Team

1. What is the specific subtype of my breast cancer (HER2 status, hormone receptor status, grade)?
2. Which preoperative therapy regimen do you recommend for my case, and why?
3. How will we monitor my response to treatment during the preoperative phase?
4. What happens if my cancer doesn't respond well to the initial therapy?
5. After preoperative therapy, will I need radiation therapy, and what would that involve?
6. What is my expected pathologic response, and what does that mean for my long-term outlook?

Important Context

According to NCCN Guidelines, not all patients are appropriate candidates for preoperative systemic therapy. Your oncologist will determine the best approach based on:

• Accurate clinical staging at baseline
• Your overall health and performance status
• Specific cancer characteristics
• Your personal preferences and goals of care

The NCCN emphasizes that accurate staging before starting treatment is critical to ensure you receive the most appropriate therapy for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.